RQ Biotechnology
Pre-clinicalRQ Bio develops long-acting monoclonal antibodies for seasonal influenza, offering immediate, potent, and lasting protection against severe disease.
Founded
2021
Focus
AntibodiesBiologics
About
RQ Bio develops long-acting monoclonal antibodies for seasonal influenza, offering immediate, potent, and lasting protection against severe disease.
Funding History
1Total raised: $3M
Seed$3MUndisclosedJun 15, 2022
Company Info
TypePrivate
Founded2021
LocationLondon, United Kingdom
StagePre-clinical
Contact
SIMILAR COMPANIES
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Pre-clinical · Oxford
AbOliGo
Pre-clinical · London
Bigespas
Pre-clinical · London
Actimed Therapeutics
Pre-clinical · London
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile